Trends in Nanopharmaceutical Patents

International Journal of Molecular Sciences

Adelaide Antunes¹  Iolanda Fierro¹  Rafaela Guerrante¹  Flavia Mendes² 

[1] National Institute of Industrial Property (Brazil), Mayrink Veiga, n° 9 Centro, Rio de Janeiro, Brazil; E-Mails:;Federal University of Rio de Janeiro, Postgraduate Program on Technology of Chemical & Biochemical Processes, Av. Horácio Macedo, 2030, Centro de Tecnologia, Bloco I sala I-222, Cidade universitária, Rio de Janeiro, Brazil; E-Mail:

关键词: health;    patents;    nanotechnology;    pharmaceutical;   

DOI  :  10.3390/ijms14047016

来源: mdpi

【 摘 要 】

Investment in nanotechnology is now a given constant by governments, research centers and companies in both more developed countries and emerging markets. Due to their characteristics, such as high stability, ability to enable antigen identification on specific cells in the human body and controlling the release of drugs and, therefore, improving therapies, nanoparticles have been the subject of research and patent applications in the pharmaceutical field. According to the Organization for Economic Co-operation and Development (OCDE), patent data can be used as a source of information in order to measure science and technology activities. Thereby, this paper presents an analysis based on patent documents related to nanotechnology in the pharmaceutical sector. As a result, the analysis of patents demonstrate primarily that nanobiotechnology attracts high levels of R&D investments, including nanoparticle-based chemotherapeutic agents/drugs, monoclonal antibody nanoparticle complexes and their role in drug delivery or contrast agents with non-toxic effects.

【 授权许可】

CC BY   
© 2013 by the authors; licensee MDPI, Basel, Switzerland